---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-22-085661"
form_type: "8-K"
ticker: "ATXI"
cik: "0001644963"
company_name: "AVENUE THERAPEUTICS, INC."
filed_at: "2022-08-03T23:59:59+00:00"
generated_at: "2026-06-24T05:14:14.701522+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Avenue Therapeutics appoints Alexandra MacLean, M.D. as CEO

## Summary
- Alexandra MacLean, M.D., appointed CEO effective August 1, 2022.
- Dr. MacLean previously an Entrepreneur in Residence at Fortress Biotech (FBIO).
- She will receive an annual cash salary of $332,200; no employment agreement yet.
- David Jin ends interim CEO role, remains interim CFO and COO.
- No family relationships or transactions requiring disclosure under Item 404(a).

## SEC filing metadata
- accession: 0001104659-22-085661
- form_type: 8-K
- ticker: ATXI
- cik: 0001644963
- company_name: AVENUE THERAPEUTICS, INC.
- filed_at: 2022-08-03T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1644963/000110465922085661/0001104659-22-085661-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1644963/000110465922085661/tm2222416d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-22-085661
- JSON: https://secwatch.observer/filing/0001104659-22-085661.json
- Plain text: https://secwatch.observer/filing/0001104659-22-085661.txt

## Key facts
- Executive change
  David Jin changed role as Interim Chief Executive Officer at AVENUE THERAPEUTICS, INC..
  - Action: ended his term as
  - Role: Interim Chief Executive Officer
  source text: With the appointment of Dr. MacLean as the new Chief Executive Officer, Mr. David Jin will end his term as interim Chief Executive Officer and will continue his responsibilities as Interim Chief Financial Officer and Chief Operating Officer of the Company.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1644963/000110465922085661/0001104659-22-085661-index.htm
- Executive change
  Alexandra MacLean, M.D. was appointed as Chief Executive Officer at AVENUE THERAPEUTICS, INC..
  - Action: appointed
  - Role: Chief Executive Officer
  source text: On August 1, 2022, the Board of Directors of Avenue Therapeutics, Inc. (the “ Company ”) appointed Alexandra MacLean, M.D., to serve as the Company’s Chief Executive Officer, with immediate effect.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1644963/000110465922085661/0001104659-22-085661-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.